Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24289Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Christou, L. | en |
| dc.contributor.author | Hatzimichael, E. C. | en |
| dc.contributor.author | Sotsiou-Candila, F. | en |
| dc.contributor.author | Siamopoulos, K. | en |
| dc.contributor.author | Bourantas, K. L. | en |
| dc.date.accessioned | 2015-11-24T19:40:02Z | - |
| dc.date.available | 2015-11-24T19:40:02Z | - |
| dc.identifier.issn | 0001-5792 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24289 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adult | en |
| dc.subject | Amyloidosis/complications/*drug therapy | en |
| dc.subject | Antineoplastic Agents/*therapeutic use | en |
| dc.subject | Humans | en |
| dc.subject | Immunoglobulin Light Chains/*metabolism | en |
| dc.subject | Interferon-alpha/*therapeutic use | en |
| dc.subject | Male | en |
| dc.subject | Melphalan/therapeutic use | en |
| dc.subject | Multiple Myeloma/complications/*drug therapy/metabolism | en |
| dc.subject | Nephrotic Syndrome/complications/*drug therapy/metabolism | en |
| dc.subject | Prednisone/therapeutic use | en |
| dc.subject | Remission Induction | en |
| dc.subject | Survivors | en |
| dc.title | A patient with multiple myeloma, amyloidosis and light-chain deposition disease in kidneys with a long survival | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10436302 | - |
| heal.identifier.secondary | http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000040954 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1999 | - |
| heal.abstract | We report a case of a 39-year-old man with lambda-light-chain multiple myeloma, nephrotic syndrome due to lambda-light-chain deposition disease in kidneys and amyloidosis in other tissues. The patient was treated with melphalan and prednisone for 1 year. After that, he was administered interferon-alpha2b (IFN-alpha2b; 3 MU, 3 times a week) as maintenance therapy for 2 years. At present, 5 years and 6 months after the initial diagnosis, the patient receives IFN-alpha2b (3 MU, twice a week) and remains in complete haematological remission. | en |
| heal.journalName | Acta Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
